Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
- Published In:
- Journal of diabetes science and technology, 8(5), 1011-7 (2014)
- Authors:
- Renukuntla, Venkat Sasidhar, Ramchandani, Neesha, Trast, Jeniece, Cantwell, Martin, Heptulla, Rubina A
- Database ID:
- RPEP-02483
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02483APA
Renukuntla, Venkat Sasidhar; Ramchandani, Neesha; Trast, Jeniece; Cantwell, Martin; Heptulla, Rubina A. (2014). Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.. Journal of diabetes science and technology, 8(5), 1011-7. https://doi.org/10.1177/1932296814542153
MLA
Renukuntla, Venkat Sasidhar, et al. "Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.." Journal of diabetes science and technology, 2014. https://doi.org/10.1177/1932296814542153
RethinkPeptides
RethinkPeptides Research Database. "Role of glucagon-like peptide-1 analogue versus amylin as an..." RPEP-02483. Retrieved from https://rethinkpeptides.com/research/renukuntla-2014-role-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.